About nutriband inc - NTRB
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. It operates through the Pocono Pharmaceuticals and 4P Therapeutics segments. The Pocono Pharmaceuticals segment relates to a coated products manufacturing entity. The 4P Therapeutics segment performs contract research and development services. The company was founded by Gareth R. Sheridan and Serguei Melnik in 2012 and is headquartered in Orlando, FL.
NTRB At a Glance
Nutriband, Inc.
121 South Orange Avenue
Orlando, Florida 32801
| Phone | 1-407-377-6695 | Revenue | 2.04M | |
| Industry | Medical Specialties | Net Income | -8,229,632.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 01 / 2027 | |||
| View SEC Filings |
NTRB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 27.378 |
| Price to Book Ratio | 8.721 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.331 |
| Enterprise Value to Sales | 25.254 |
| Total Debt to Enterprise Value | 0.005 |
NTRB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 17.201 |
| Total Asset Turnover | 0.271 |
NTRB Liquidity
| Current Ratio | 6.361 |
| Quick Ratio | 6.21 |
| Cash Ratio | 5.833 |
NTRB Profitability
| Gross Margin | 25.685 |
| Operating Margin | -408.414 |
| Pretax Margin | -404.077 |
| Net Margin | -404.077 |
| Return on Assets | -109.598 |
| Return on Equity | -125.563 |
| Return on Total Capital | -118.84 |
| Return on Invested Capital | -124.214 |
NTRB Capital Structure
| Total Debt to Total Equity | 3.675 |
| Total Debt to Total Capital | 3.545 |
| Total Debt to Total Assets | 3.252 |
| Long-Term Debt to Equity | 1.261 |
| Long-Term Debt to Total Capital | 1.215 |